vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and SMITH MIDLAND CORP (SMID). Click either name above to swap in a different company.

AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $23.1M, roughly 1.9× SMITH MIDLAND CORP). SMITH MIDLAND CORP runs the higher net margin — 9.2% vs -19.9%, a 29.2% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 24.7%). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 17.4%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Smith Midland Corp is a specialized manufacturer of precast concrete products for infrastructure, commercial, residential and industrial construction uses. Its key product lines include highway safety barriers, acoustic sound walls, architectural precast panels, and stormwater management systems, serving primarily the North American market with durable, sustainable construction solutions.

ABCL vs SMID — Head-to-Head

Bigger by revenue
ABCL
ABCL
1.9× larger
ABCL
$44.9M
$23.1M
SMID
Growing faster (revenue YoY)
ABCL
ABCL
+763.7% gap
ABCL
788.4%
24.7%
SMID
Higher net margin
SMID
SMID
29.2% more per $
SMID
9.2%
-19.9%
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
17.4%
SMID

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABCL
ABCL
SMID
SMID
Revenue
$44.9M
$23.1M
Net Profit
$-8.9M
$2.1M
Gross Margin
57.5%
Operating Margin
-63.7%
37.8%
Net Margin
-19.9%
9.2%
Revenue YoY
788.4%
24.7%
Net Profit YoY
73.9%
52.5%
EPS (diluted)
$-0.03
$0.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
SMID
SMID
Q4 25
$44.9M
$23.1M
Q3 25
$9.0M
$21.5M
Q2 25
$17.1M
$26.2M
Q1 25
$4.2M
$22.7M
Q4 24
$5.0M
$18.5M
Q3 24
$6.5M
$23.6M
Q2 24
$7.3M
$19.6M
Q1 24
$10.0M
$16.8M
Net Profit
ABCL
ABCL
SMID
SMID
Q4 25
$-8.9M
$2.1M
Q3 25
$-57.1M
$2.9M
Q2 25
$-34.7M
$4.2M
Q1 25
$-45.6M
$3.3M
Q4 24
$1.4M
Q3 24
$-51.1M
$3.1M
Q2 24
$-36.9M
$2.0M
Q1 24
$-40.6M
$1.1M
Gross Margin
ABCL
ABCL
SMID
SMID
Q4 25
57.5%
Q3 25
26.8%
Q2 25
0.0%
Q1 25
30.7%
Q4 24
51.4%
Q3 24
27.9%
Q2 24
0.0%
Q1 24
23.3%
Operating Margin
ABCL
ABCL
SMID
SMID
Q4 25
-63.7%
37.8%
Q3 25
-851.8%
18.0%
Q2 25
-290.2%
0.0%
Q1 25
-1479.6%
19.3%
Q4 24
24.5%
Q3 24
-1439.4%
16.3%
Q2 24
-1276.2%
0.0%
Q1 24
-551.5%
9.0%
Net Margin
ABCL
ABCL
SMID
SMID
Q4 25
-19.9%
9.2%
Q3 25
-637.8%
13.4%
Q2 25
-203.3%
15.9%
Q1 25
-1077.2%
14.7%
Q4 24
7.5%
Q3 24
-785.4%
13.4%
Q2 24
-504.3%
10.1%
Q1 24
-408.0%
6.8%
EPS (diluted)
ABCL
ABCL
SMID
SMID
Q4 25
$-0.03
$0.41
Q3 25
$-0.19
$0.54
Q2 25
$-0.12
$0.79
Q1 25
$-0.15
$0.62
Q4 24
$0.28
Q3 24
$-0.17
$0.59
Q2 24
$-0.13
$0.37
Q1 24
$-0.14
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
SMID
SMID
Cash + ST InvestmentsLiquidity on hand
$128.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$966.9M
$54.3M
Total Assets
$1.4B
$87.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
SMID
SMID
Q4 25
$128.5M
Q3 25
$83.2M
Q2 25
$92.4M
Q1 25
$159.3M
Q4 24
$156.3M
Q3 24
$126.6M
Q2 24
$148.3M
Q1 24
$123.6M
Stockholders' Equity
ABCL
ABCL
SMID
SMID
Q4 25
$966.9M
$54.3M
Q3 25
$964.0M
$52.1M
Q2 25
$1.0B
$49.2M
Q1 25
$1.0B
$45.1M
Q4 24
$1.1B
$41.7M
Q3 24
$1.1B
$40.3M
Q2 24
$1.1B
$37.2M
Q1 24
$1.1B
$35.3M
Total Assets
ABCL
ABCL
SMID
SMID
Q4 25
$1.4B
$87.7M
Q3 25
$1.4B
$85.4M
Q2 25
$1.4B
$81.2K
Q1 25
$1.3B
$74.7M
Q4 24
$1.4B
$68.0M
Q3 24
$1.4B
$66.6M
Q2 24
$1.4B
$64.0M
Q1 24
$1.5B
$64.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
SMID
SMID
Operating Cash FlowLast quarter
$-34.7M
Free Cash FlowOCF − Capex
$-44.6M
FCF MarginFCF / Revenue
-99.4%
Capex IntensityCapex / Revenue
21.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-174.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
SMID
SMID
Q4 25
$-34.7M
Q3 25
$-52.6M
$11.7M
Q2 25
$-32.4M
Q1 25
$-11.6M
$2.2M
Q4 24
$-108.6M
$-645.0K
Q3 24
$-28.9M
$3.9M
Q2 24
$-30.0M
$2.7M
Q1 24
$-41.7M
$-777.0K
Free Cash Flow
ABCL
ABCL
SMID
SMID
Q4 25
$-44.6M
Q3 25
$-61.5M
$6.3M
Q2 25
$-45.8M
Q1 25
$-22.2M
$1.6M
Q4 24
$-187.0M
$-1.3M
Q3 24
$-47.4M
$1.8M
Q2 24
$-50.1M
$998.0K
Q1 24
$-65.8M
$-2.6M
FCF Margin
ABCL
ABCL
SMID
SMID
Q4 25
-99.4%
Q3 25
-687.0%
29.5%
Q2 25
-267.9%
Q1 25
-524.0%
7.1%
Q4 24
-3702.8%
-7.0%
Q3 24
-728.4%
7.8%
Q2 24
-683.8%
5.1%
Q1 24
-661.5%
-15.3%
Capex Intensity
ABCL
ABCL
SMID
SMID
Q4 25
21.9%
Q3 25
99.7%
25.1%
Q2 25
78.2%
Q1 25
251.1%
2.6%
Q4 24
1552.7%
3.6%
Q3 24
284.6%
8.6%
Q2 24
274.6%
8.7%
Q1 24
242.5%
10.7%
Cash Conversion
ABCL
ABCL
SMID
SMID
Q4 25
Q3 25
4.07×
Q2 25
Q1 25
0.67×
Q4 24
-0.46×
Q3 24
1.23×
Q2 24
1.37×
Q1 24
-0.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABCL
ABCL

Segment breakdown not available.

SMID
SMID

Product Sales$13.8M60%
Service Revenue$9.3M40%

Related Comparisons